Summary
65 / 100 · Bulios Score
What speaks for it
- It earns 18 USD a year on every 100 USD of invested capital.
- Out of every 100 USD of revenue, 16 USD is left as free cash.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue growth is slowing: 3.5% a year over the last 3 years against 12% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
P/E against the industry (Medical - Devices)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 16.8 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 3.5% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 32 USD
- Research and development 2.0 USD
- Sales and administration 55 USD
- Taxes and other 1.3 USD
- Net profit 9.4 USD
Net profit, industry median (Medical - Devices) 33 USD
Out of every 100 USD of revenue, 9.4 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $18.33 is 35% above today's price. 71% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- U.S. Segment 88%
- International Segment 12%
By region
- UNITED STATES 88%
- Non-US 12%
U.S. Segment brings in 88% of revenue.
Segments in detail